assignment

Not Yet Recruiting

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Trial ID: 2022-501703-27-00
Protocol: XL092-304
Sponsor: Exelixis Inc.

Trial statistics

science

test molecules

location_city

research sites

public

countries

medical_information

disease

person_search

investigators

handshake

vendors

Diseases & Conditions

Renal cell carcinoma

Objectives

The primary objective of this study is to evaluate the efficacy of XL092 in combination with nivolumab compared to sunitinib in subjects with unresectable, locally advanced, or metastatic non-clear cell renal cell carcinoma. 5

Secondary objectives include:

Assessment of safety and tolerability. 4
Characterization of pharmacokinetics, quality of life, biomarkers, and healthcare resource utilization. 6

Participants

This study involves 183 participants diagnosed with non-clear cell renal cell carcinoma. The study population includes both male and female individuals, with ages ranging from 18 to 65 years. Eligible participants must have unresectable, locally advanced, or metastatic disease, including papillary, unclassified, or translocation-associated histological subtypes. Inclusion requires measurable disease according to RECIST 1.1 and the availability of tumor biopsy material. Participants must demonstrate a Karnofsky Performance Status of 70% or higher and maintain adequate organ function and marrow function. Female subjects of childbearing potential must not be pregnant, and all sexually active participants must utilize highly effective contraception during the study and for specified durations following the final dose of treatment.

Plans and Procedures

This Phase 3, randomized, open-label study aims to evaluate the efficacy of XL092 in combination with nivolumab compared to sunitinib in subjects with non-clear cell renal cell carcinoma that is advanced or metastatic. The primary endpoints include progression-free survival and objective response rate as assessed by a blinded independent radiology committee, while overall survival is evaluated as a secondary endpoint. The study involves a screening phase to confirm eligibility through histological, laboratory, and clinical assessments, followed by randomization to either the test or comparator group. The trial is estimated to conclude by June 30, 2028. Participant involvement is subject to protocol compliance, including adherence to contraceptive requirements and the management of adverse events. Early termination from the study may occur based on clinical judgment or protocol-defined conditions.

Treatment

The experimental treatment consists of XL092, which is administered as a 100 mg tablet via the oral route. This substance contains n-(4-fluorophenyl)-n-(4-((7-methoxy-6-(methylcarbamoyl)quinolin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide.

The experimental treatment also includes nivolumab, provided as OPDIVO 10 mg/mL concentrate for solution for infusion. The dosage is 480 mg administered via intravenous infusion.

The comparator treatment is sunitinib, administered as hard capsules via the oral route at a dosage of 50 mg. This is provided in the form of Sunitinib AqVida 12,5 mg and 25 mg capsules.

Efficacy

The efficacy of the combination of XL092 and nivolumab compared to sunitinib will be evaluated in subjects with non-clear cell renal cell carcinoma. The primary endpoints include the progression-free survival duration and the objective response rate. These parameters will be assessed according to the Response Evaluation Criteria in Solid Tumors version 1.1 by a Blinded Independent Radiology Committee.

Secondary endpoints consist of the duration of overall survival.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

Histologically confirmed nccRCC that is unresectable, advanced or metastatic. Histologic subtypes including papillary, unclassified, and translocation-associated are allowed. Among the eligible histologic subtypes, sarcomatoid features are allowed.
Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1; Eisenhauer et al 2009) as determined by the Investigator. Measurable disease must be outside the radiation field if radiation therapy was previously administered.
Available archival tumor biopsy material. If archival tissue is unavailable, must provide fresh tumor tissue biopsy prior to randomization.
Recovery to baseline or ≤ Grade 1 per CTCAE v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.
Age 18 years or older on the day of consent.
Karnofsky Performance Status (KPS) ≥ 70%.
Adequate organ and marrow function, based upon all of the following laboratory assessments within 14 days prior to randomization: a. Absolute neutrophil count (ANC) ≥ 1500/μL (≥ 1.5 GI/L) without granulocyte colony stimulating factor (G-CSF) support within 2 weeks before screening laboratory sample collection. b. Platelets ≥ 100,000/μL (≥ 100 GI/L) without transfusion within 2 weeks before screening laboratory sample collection. c. Hemoglobin ≥ 9 g/dL (≥ 90 g/L) without transfusion within 1 week before screening laboratory sample collection and no clinical evidence of bleeding. d. International Normalized Ratio (INR) ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.2 × upper limit of normal (ULN). e. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 × ULN. f. f. Total bilirubin ≤ 1.5 × ULN (with the exception that total bilirubin for subjects with Gilbert’s disease ≤ 3 × ULN). g. g. Calculated creatinine clearance ≥ 40 mL/min (≥ 0.67 mL/sec) using the Cockcroft-Gault equation. h. h. Urine protein-to-creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol), or 24-h urine protein ≤ 1 g. i. i. Negative hepatitis B surface antigen (HBsAg) test. j. j. Negative hepatitis C virus (HCV) antibody test, or positive HCV antibody test followed by a negative HCV RNA test and no ongoing anti-HCV therapy. Note: The HCV RNA test will be performed only for subjects who have a positive HCV antibody test.
Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.
Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and for the following durations after the last dose of study treatment (whichever is later): • through 186 days after the last dose of XL092 for women of childbearing potential (WOCBP) or 96 days after the last dose of XL092 for men, • at least 5 months for women after the last dose of nivolumab • at least 4 weeks after the last dose of sunitinib for WOCBP or 7 weeks after the last dose for men An additional contraceptive method, such as a barrier method (eg, condom), is also required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods.
Female subjects of childbearing potential must not be pregnant at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of other biological or physiological causes. In addition, females < 55 years-of-age must have a serum follicle stimulating hormone (FSH) level > 40 mIU/mL to confirm menopause). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.

cancel

Exclusion Criteria

Chromophobe, renal medullary carcinoma, and pure collecting duct histologic subtypes of nccRCC.
Prior systemic anticancer therapy for unresectable locally advanced or metastatic nccRCC including investigational agents. Note: One prior systemic adjuvant therapy, including ICI therapy and excluding sunitinib, is allowed for completely resected RCC and if recurrence occurred at least 6 months after the last dose of adjuvant therapy.
Radiation therapy for bone metastases within 2 weeks, any other radiation therapy within 4 weeks prior to randomization. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy (including radiosurgery) or surgically removed and stable for at least 4 weeks before randomization. Note: Subjects with an incidental finding of an isolated brain lesion < 1 cm in diameter may be eligible after Sponsor approval if the lesion is radiographically stable for 4 weeks before randomization and does not require treatment per Investigator judgement. Note: Eligible subjects must be neurologically asymptomatic and either off corticosteroids, or on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to randomization. Imaging performed within 28 days prior to randomization must document radiographic stability of CNS lesions, and must be performed after completion of any CNS-directed therapy. A stable dose of anticonvulsants is allowed.
Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat nccRCC within 2 weeks before randomization.
Concomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors) and platelet inhibitors (eg, clopidogrel). Subjects who are receiving oral anticoagulants at the time of screening must be transitioned to LMWH prior to randomization with the last dose of oral anticoagulants at least 3 days or 5 half-lives prior to randomization, whichever is longer. Subjects who require treatment with platelet inhibitors (eg, clopidogrel) are not eligible. Allowed anticoagulants are: − Low-dose aspirin for cardioprotection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH), − Therapeutic doses of LMWH in subjects without known brain metastases.
The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: a. Cardiovascular disorders: i. Congestive heart failure (CHF) class III or IV as defined by the New York Heart Association, unstable angina pectoris, serious cardiac arrhythmias (eg, ventricular flutter, ventricular fibrillation, Torsades de pointes). ii. Uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment. iii. Stroke (including transient ischemic attack [TIA]), myocardial infarction, pulmonary embolism (PE), prior clinically significant venous or other arterial ischemic event within 6 months before randomization. iv. Deep vein thrombosis (DVT) within 3 months prior to randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization. b. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation: i. Tumors invading the GI tract from external viscera. ii. Active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis. iii. Acute obstruction of the bowel, gastric outlet, or pancreatic or biliary duct within 6 months before randomization unless cause of obstruction is definitively managed and subject is asymptomatic. iv. Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intraabdominal abscess within 6 months before randomization. v. Known gastric or esophageal varices. c. Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 mL) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 12 weeks before randomization. d. Cavitating pulmonary lesion(s) or known endobronchial disease manifestation. e. Lesions invading major blood vessel including, but not limited to, inferior vena cava, pulmonary artery, or aorta. f. Other clinically significant disorders such as: i. Any active, known or suspected autoimmune disease ii. Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to randomization. iii. Active infection requiring systemic antimicrobial treatment (antibiotics, antimycotic, antiviral). iv. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness. v. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. vi. Known or suspected infection with SARS-CoV-2 within 4 weeks before randomization. vii. Serious non-healing wound/ulcer/bone fracture per Investigator judgment. viii. Clinically significant malabsorption syndrome per Investigator judgment. ix. Pharmacologically uncompensated/symptomatic hypothyroidism. x. Moderate to severe hepatic impairment (Child-Pugh B or C) or known cirrhosis. xi. Requirement for hemodialysis or peritoneal dialysis. xii. History of solid organ or allogeneic stem cell transplant. xiii. History of life-threatening toxicity related to prior immune therapy (eg, anti-PD-1/PD-L1 treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) except those that are unlikely to recur and manageable by standard of care treatment (eg, hypothyroidism).
Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 8 weeks prior to randomization. Prior laparoscopic nephrectomy within 4 weeks prior to randomization. Minor surgery (eg, simple excision, tooth extraction) within 10 days before randomization. Complete wound healing from major or minor surgery must have occurred at least prior to randomization. Note: Fresh tumor biopsies should be performed at least 7 days before randomization. Subjects with clinically relevant ongoing complications from prior surgical procedures, including biopsies, are not eligible.
Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per electrocardiogram (ECG) within 14 days before randomization. Note: Triplicate ECG evaluations will be performed and the average of these consecutive results for QTcF will be used to determine eligibility.
History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent.
Pregnant or lactating females.
Inability or unwillingness to swallow tablets or receive IV administration, or presence of GI condition that might affect the absorption of study drug (eg, PEG tube).
Previously identified allergy or hypersensitivity to components of the study treatment formulations or history of severe infusion-related reactions to monoclonal antibodies.
Any other active malignancy within 2 years prior to randomization, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy. Incidentally diagnosed prostate cancer is allowed if assessed as stage ≤ T2N0M0 and Gleason score ≤ 6.
Administration of a live, attenuated vaccine within 30 days before randomization. Note: If feasible, approved non-live vaccines for SARS-CoV-2 should be administered at least 2 weeks before randomization.

Trial Status by Country

Country	Status	Start of Recruitment	Planned Patients
Bulgaria	Not Recruiting	01 Sept 2023	4
Croatia	Not Recruiting	01 Sept 2023	4
Czechia	Not Recruiting	01 Sept 2023	9
Denmark	Not Yet Recruiting	01 Sept 2023	3
Finland	Not Recruiting	01 Sept 2023	3
France	Not Recruiting	01 Sept 2023	38
Germany	Not Recruiting	01 Sept 2023	12
Greece	Not Recruiting	01 Sept 2023	10
Hungary	Not Recruiting	01 Sept 2023	7
Italy	Not Recruiting	01 Sept 2023	34

1–10 of 15

1 / 2

Sites & Investigators

Research sites

Klinički bolnički centar Zagreb (University Hospital Center Zagreb)Hospital Vall d’Hebron IRCCS Humanitas Research Hospital Fakultni Thomayerova nemocnice

Investigators

Ralf E.Cristian L.Charlotte J.Javier M. C.

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name	Role in Trial	Formulation	Administration	Max Daily Dose	Treatment Duration	EU MP Number
Sunitinib AqVida 25 mg Hartkapseln	Comparator	HARTKAPSELN	ORAL	50	252	PRD6481409
XL092	Test	TABLET	ORAL	100	252	PRD10205739
Sunitinib AqVida 12,5 mg Hartkapseln	Comparator	HARTKAPSELN	ORAL	50	252	PRD6481408
XL092	Test	TABLET	ORAL	100	252	PRD10205699
XL092	Test	TABLET	ORAL	100	252	PRD10205698
OPDIVO 10 mg/mL concentrate for solution for infusion.	Test	CONCENTRATE FOR SOLUTION FOR INFUSION	INTRAVENIOUS INFUSION	480	104	PRD2941375